Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$1.7 million.

  • Anika Therapeutics' Cash from Investing Activities rose 462.56% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 7850.46%. This contributed to the annual value of -$8.3 million for FY2024, which is 5356.55% down from last year.
  • As of Q3 2025, Anika Therapeutics' Cash from Investing Activities stood at -$1.7 million, which was up 462.56% from -$539000.0 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cash from Investing Activities ranged from a high of $1.7 million in Q1 2021 and a low of -$3.4 million during Q2 2024
  • Its 5-year average for Cash from Investing Activities is -$1.3 million, with a median of -$1.5 million in 2023.
  • In the last 5 years, Anika Therapeutics' Cash from Investing Activities crashed by 17647.06% in 2022 and then soared by 19247.79% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Cash from Investing Activities stood at -$1.2 million in 2021, then crashed by 103.95% to -$2.5 million in 2022, then grew by 27.24% to -$1.8 million in 2023, then grew by 28.97% to -$1.3 million in 2024, then crashed by 32.52% to -$1.7 million in 2025.
  • Its Cash from Investing Activities was -$1.7 million in Q3 2025, compared to -$539000.0 in Q2 2025 and $1.7 million in Q1 2025.